Stabilized Marine Lipid Extract Coming from New Zealand Green Mussel. Lyprinol ® is a patented extract oil green lipped mussel from New Zealand (Perna canaliculus) contains a unique group of Omega 3 fatty Elcosatetraenoicos. Lyprinol ® ensures that each bead contains 50 mg. purest oil with an extremely active profile thanks to its patented process of isolation, stabilization and concentration of natural active ingredients. This product is free of marine proteins making it suitable for people with allergies to shellfish. The characteristic odor and cloudy which may occur in this product are normal and have no effect on quality. Each pearl provides 150 mg. fatty acid and 1.3 calories. This product contains no carbohydrates or proteins. Packaging in the EU. Natural marine lipid extract, a powerful anti-inflammatory. A new natural marine lipid extract patented stabilized combination includes a rare group of lipids and omega-3 polyunsaturated. Lyprinol ® has been shown through clinical research, a compound with an extremely potent anti-inflammatory and antiarthritic activity. This unique marine product has been exposed to critical review by numerous research institutions around the world and after it has demonstrated a significant anti-inflammatory activity in vitro by inhibiting the synthesis of leukotrienes and in vivo by the marked reduction in severity of polyarthritis induced in rats. Several publications have confirmed these results and recent completion of a double-blind study in humans conducted in Glasgow in Scotland Hospital also confirmed these results. Leukotrienes are formed in the body through the lipoxygenase pathway and are responsible for the initiation and extension of the inflammatory process. The work carried out by the Queen Elizabeth Hospital and the University of Adelaide in Australia have clearly demonstrated that the stabilized marine lipid Lyprinol ® is a potent inhibitor of the pathway of 5-lipoxygenase, because this greatly reduces the harmful effects of chronic inflammation that can be found in various allergic reactions such as arthritis and other inflammatory disorders such as asthma. Because many of the currently used anti-inflammatory drugs, particularly NSAIDs NSAIDs, work through the cyclo-oxygenase pathway, much research and recent international efforts have been directed toward the development of inhibitors of the second largest inflammatory pathway, of lipoxygenase. There is little doubt that Lyprinol ® can provide a powerful means to control and inhibit the damage caused by excessive inflammatory responses in the body. In vivo studies undertaken by the University of Quuensland in Australia testing the anti-arthritic properties of Lyprinol ®. Using standard models for assessing the power of conventional arthritis drugs, Lyprinol ® ™ was measured against its ability to reduce edema associated with induced polyarthritis in rats. It was published in the journal Inflammopharmacology. The results were spectacular, Lyprinol ® reduced the edema in joints up to 93% compared with untreated control groups. Following these discoveries leading scientists from the University of Quuensland focused Lyprinol ® then compare two widely used drugs, called Indomethacin and Ibuprofen. When it was delivered to the same dose (5 mg / kg / day) Lyprinol ® outscored the drugs indomethacin and ibuprofen by a ratio of 2:1. This was an amazing successful outcome for Lyprinol ®. More recently a double-blind clinical trial conducted by the University Hospital of West Glasgow NHS involving 60 patients, 30 of whom had a classical rheumatoid arthritis and the other 30 with clinical and radiological evidence of osteoarthritis, showed excellent results. Both patients who suffered from rheumatism and osteoarthritis showed significant improvements, 76% of rheumatic and 70% of osteoarthritic benefited in the experiment. 79% and 80% respectively if we exclude dropouts. These results have been published in the journal Complementary Therapies in Medicine. (Sept.1998) A similar pilot study conducted in Denmark showed that Lyprinol ™ dramatically reduced the level of pain over a period of 2 to 3 months in patients with osteoarthritis. The study is currently being expanded. These findings prompted a series of subsequent studies conducted to evaluate the ability of Lyprinol ® compared with other healthy food products to which they also attribute anti-arthritic properties. Lyprinol ® was compared with Flax Oil, Evening Primrose Oil, Salmon Oil and Max EPA (fish) through the test of induced polyarthritis. Studies Whitehouse - Inflammopharmacology 1 +2 A dose of Lyprinol ® for a body weight basis is 100 times more potent than Max EPA 125 times more potent than powdered green lipped mussel (not concentrated) 175 times more potent than the oil Evening Primrose 175 times more potent than Salmon Oil and 200 times more potent than Flax Oil in the regulation of inflammation associated with arthritis edematous